US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
HE

HELPStockCYBIN INC.

Nasdaq Global Market · Healthcare · CA

$10.69 last close 2026-10-19
Open in terminalCompare
Alert

Verdicts genuinely change. Free email alert the moment HELP's does — no target price to set, unlike "Alert" above.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol
0 of 6 pass our own screen — 1 of 7 could not be computed
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 73.9% aligned
VWAPPrice holding above VWAP ($10.45)
VolumeRelative volume 5.0× the 20-day average
Momentum10-day rate of change -6.4%
Market & analysts
Wall Street consensus
BUY
8 analysts
Price target
$40.55
+279.3% · 10 analysts
Institutional own.
42.0%
of shares
Momentum (10d)
-6.4%
rate of change
SMC grade
C · 55
73.9% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
C · 55
SMC grade — 73.9% timeframe alignment
-6.4%
Rate of change (10d)
BUY
Wall Street consensus (8)
$40.55
Price target (+279.3%) · 10 analysts
42.0%
Institutional ownership

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2025-03-31. HELP files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.

Business activity: cleared (no excluded categories detected)

AAOIFI Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed

RatioValueThresholdResult
Interest-bearing debt 0.00% 30.00% Pass
Interest-bearing investments 10.53% 30.00% Pass

Usmani Fail

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass
Interest-bearing investments 52.21% 33.00% Fail
Non-liquid assets 45.52% at least 20.00% Pass

MSCI Fail

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass
Cash + interest-bearing securities 52.21% 33.33% Fail
Accounts receivable 54.48% 33.33% Fail

FTSE Fail

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass
Cash + interest-bearing securities 52.21% 33.33% Fail
Accounts receivable 54.48% 50.00% Fail

Dow Jones Islamic Market Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass
Cash + interest-bearing securities 24.87% 33.00% Pass
Accounts receivable 1.08% 33.00% Pass

S&P Shariah Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.00% Pass
Cash + interest-bearing securities 27.66% 49.00% Pass
Accounts receivable 1.21% 49.00% Pass

MSCI M-Series Unverified⚠️ a figure this standard divides by was not available, so it could not be scored — the rows below show what was and was not computed

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 0.00% 33.33% Pass
Cash + interest-bearing securities 27.66% 33.33% Pass
Accounts receivable 28.87% 49.00% Pass

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)nonliquid assets ratio · floor 25.5pts
Usmani (% of total assets)debt ratio 33.0pts
MSCI Islamic Index (% of total assets)debt ratio 33.3pts
MSCI Islamic Index (% of total assets)receivables ratio 21.2pts
Usmani (% of total assets)investments ratio 19.2pts
MSCI Islamic Index (% of total assets)cash and interest ratio 18.9pts

The numbers the ratios are built from

Read from HELP's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period not measured — —
Interest-bearing debtShort and long-term borrowings $0 2025-03-31 no debt tag reported in 3+ years (treated as $0)
Cash and interest-bearing securitiesCash, equivalents and marketable securities $94.0M 2025-03-31 CashAndCashEquivalents
Total assetsBalance sheet total $180.1M 2025-03-31 Assets
Market capDenominator for AAOIFI $892.9M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $156.3M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $159.0M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $0 2025-03-31 no interest-income tag reported in 3+ years (treated as $0)

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

What changed, and when

Verdict history for HELP. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for HELP has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

14.0211.488.956.413.872025-10-202026-04-212026-10-16

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
9.38
S2
9.76
S1
10.40
PIVOT
10.78
R1
11.42
R2
11.80
R3
12.44

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
10.78 – 15.69
±18.57% from 13.23, made 2026-09-10 · resolves 2026-09-17
STRONG BUY
from 19 indicators
61.9% of our last 5789 forecasts landed inside their stated range, and 49.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

SELL
19 indicators
OscillatorsSELL
2 buy · 2 neutral · 3 sell
Moving averagesSTRONG SELL
4 buy · 0 neutral · 8 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)41.80NEUTRAL
Stochastic %K (14)19.37BUY
CCI (20)-83.33NEUTRAL
Williams %R (14)-80.63BUY
MACD (12,26,9)-0.16SELL
ROC (10)-9.83SELL
Momentum (10)-1.15SELL
EMA (10)11.02SELL
SMA (10)10.87SELL
EMA (20)11.46SELL
SMA (20)11.78SELL
EMA (30)11.58SELL
SMA (30)12.21SELL
EMA (50)11.24SELL
SMA (50)12.12SELL
EMA (100)9.93BUY
SMA (100)9.15BUY
EMA (200)8.49BUY
SMA (200)7.57BUY

About CYBIN INC.

Healthcare · Biotechnology

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.

helus.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 41
⏰ 4H RANGING 44
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-6.4%
Rate of change (10d)
5.0×
Volume vs its 20-day average
-0.55
MACD (no fresh cross)
$10.44
Volume POC (today)
$10.35 – $10.65
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Still fetching insider filings — it ran past this page's budget, so the page painted without waiting. The fetch is still running; reload in a moment and it will be here.

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-10-13 · Asset managers net 915835 (+9220)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.